close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Fresenius Kabi

< Previous 1 2 Next >
Fresenius Kabi Celebrates 25th Anniversary of National Blood Donation Hall of Fame by Honoring 2023 Heroes
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Introduces Smart Labels for Diprivan® with Embedded Fully Interoperable +RFID Technology
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Named 2023 Supplier Partner of the Year by Vizient
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Selected for Second Consecutive Year to Exhibit the Ivenix Infusion System at Vizient Innovative Technology Exchange
From Fresenius Kabi
Via Business Wire
Virginia Oncology Associates Chooses the Ivenix Infusion System from Fresenius Kabi
From Fresenius Kabi
Via Business Wire
Fresenius Kabi and Lupagen Enter into Strategic Development and Supply Agreement to Bring Cell and Gene Therapies to the Bedside
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Launches Plerixafor Injection
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Further Expands Radiology Portfolio with Launch of Gadobutrol Injection
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Introduces New Presentation for Fentanyl Citrate Injection, USP in Simplist® Ready-to-Administer Prefilled Syringes
From Fresenius Kabi
Via Business Wire
Expanding Access to Women’s Health Fresenius Kabi Launches Generic Fertility Treatment
From Fresenius Kabi
Via Business Wire
IDACIO® (adalimumab-aacf) Now Available in the United States
From Fresenius Kabi
Via Business Wire
Metrodora Institute, a Leader in Treating Complex Conditions, Chooses the Ivenix Infusion System from Fresenius Kabi
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Broadens Radiology Portfolio with its First-to-Market Authorized Generic, Sincalide for Injection
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Launches Vasopressin Injection, USP Expanding U.S. Critical Care Portfolio
From Fresenius Kabi
Via Business Wire
Supporting Patient Safety: Fresenius Kabi Expands Ready-to-Administer Portfolio with Diazepam Injection, USP in Simplist® Prefilled Syringe
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Launches RFID-Enabled Rocuronium Bromide Injection, its First Product Compatible with Bluesight's KitCheck System
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Awarded Technology Breakthrough Agreement with Premier, Inc. for the Ivenix Infusion System
From Fresenius Kabi
Via Business Wire
CMS grants Fresenius Kabi permanent, product-specific Q-Code for Stimufend® (pegfilgrastim-fpgk)
From Fresenius Kabi
Via Business Wire
Vizient Innovative Technology Contract Awarded to Fresenius Kabi for the Ivenix Infusion System
From Fresenius Kabi
Via Business Wire
Stimufend® (pegfilgrastim-fpgk) Now Available in the United States
From Fresenius Kabi
Via Business Wire
Fresenius Kabi’s Ivenix Infusion System Goes Live at San Luis Valley Health
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Targets Treatment of Certain Seizures with Launch of Generic Lacosamide Injection, USP
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Introduces Pralatrexate Injection for the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Introduces KabiCare Nutrition Resources for U.S. Parenteral Nutrition Products
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Announces 2022 Inductees to Blood Donation Hall of Fame
From Fresenius Kabi
Via Business Wire
Fort HealthCare Goes Live with Smart Pump Interoperability with the Ivenix Infusion System from Fresenius Kabi
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Named 2022 Pharmaceutical Supplier Partner of the Year by Vizient
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Expands Contrast Agent Portfolio with Launch of Gadoterate Meglumine Injection, USP
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Selected to Exhibit the Ivenix Infusion System at Vizient Innovative Technology Exchange
From Fresenius Kabi
Via Business Wire
Fresenius Kabi Receives U.S. FDA Approval for Biosimilar Stimufend® (pegfilgrastim - fpgk)
From Fresenius Kabi
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today